Abstract
Based on recent evidence, oxidized low-density lipoprotein (LDL) is a strong candidate for an in vivo atherogenic lipoprotein. Probucol, a drug widely used as a hypolipidemic agent, has an anti-atherosclerotic action which can be attributed to its antioxidant effect. Results from studies using probucol have suggested that oxidized LDL have an important role in atherosclerosis. In this review the effects of probucol on oxidized lipoproteins are discussed with particular reference to oxidized LDL.

This publication has 0 references indexed in Scilit: